サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1791699

治験薬CDMOの世界市場

Investigational New Drug CDMO

出版日
ページ情報
英文 162 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.73円
治験薬CDMOの世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 162 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

治験薬CDMOの世界市場は2030年までに158億米ドルに達する見込み

2024年に113億米ドルと推定される治験薬CDMOの世界市場は、2024年から2030年にかけてCAGR 5.8%で成長し、2030年には158億米ドルに達すると予測されます。本レポートで分析されているセグメントの一つである低分子は、CAGR4.7%を記録し、分析期間終了時には97億米ドルに達すると予想されています。大型分子セグメントの成長率は、分析期間中CAGR 7.6%と推定されます。

米国市場は30億米ドルと推定、中国はCAGR 5.7%で成長すると予測

米国の治験薬CDMO市場は2024年に30億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに25億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.2％と5.0％と予測されています。欧州では、ドイツがCAGR 4.8%で成長すると予測されています。

治験薬CDMO市場- 主要動向と成長促進要因のまとめ

治験薬開発・製造受託機関（CDMO）市場は、製薬およびバイオテクノロジー業界にとって重要な要素となっています。製薬企業が医薬品開発と製造をアウトソーシングしながらイノベーションに注力し続ける中、CDMOは前臨床研究から臨床試験への道のりを加速させる上で重要な役割を果たしています。INDのCDMOは、製剤開発、臨床試験材料の製造、薬事サポート、分析サービスを含むエンド・ツー・エンドのソリューションを提供することに特化しており、製薬企業が複雑な医薬品承認プロセスを効率的に進めることを可能にしています。医薬品分子の複雑化、規制要件の厳格化、専門的な専門知識への需要の高まりを考慮すると、IND市場におけるCDMOの役割は急速に拡大しており、世界中の医薬品開発の将来を形成しています。

技術の進歩はIND CDMOサービスをどのように変化させているか？

INDのCDMO市場は、医薬品開発の効率、コンプライアンス、スピードを高める技術革新によって大きな変革期を迎えています。最も重要な進歩のひとつは、製造プロセスを合理化し、無駄を最小限に抑え、製品の一貫性を向上させる連続製造技術の統合です。従来のバッチ製造とは異なり、連続製造ではリアルタイムの品質モニタリングが可能なため、ばらつきのリスクが軽減され、初期段階の医薬品製造のスケーラビリティが向上します。

業界におけるもう1つのブレークスルーは、医薬品の製剤化とプロセスの最適化における人工知能（AI）と機械学習（ML）の活用です。AIによる予測モデリングは、CDMOが最も効果的な製剤を特定し、安定性条件を最適化し、プロセス効率を高めるのに役立ちます。さらに、ラボや製造環境における自動化やロボット化によって、化合物の取り扱いの精度が向上し、人為的ミスを最小限に抑え、IND製造における再現性が確保されています。シングルユース・バイオプロセシング技術の採用も、特に生物製剤や細胞・遺伝子治療製造において、勢いを増している動向です。これらの使い捨てシステムは、汚染リスクを低減し、運用コストを下げ、柔軟性を高めるため、初期段階の臨床生産に理想的です。

どのような市場動向がIND CDMOの状況を再構築しているか？

IND CDMO市場は、その成長軌道を再構築するいくつかの主要動向を目の当たりにしています。最も顕著な動向のひとつは、生物製剤や先端治療薬に特化したCDMOサービスに対する需要の高まりです。モノクローナル抗体、細胞・遺伝子治療、RNAベースの医薬品の急速な拡大に伴い、製薬会社は、専門的なインフラと規制に関する知識を必要とする複雑な生物学的製剤の取り扱いに精通したCDMOを求めています。このシフトにより、多くのCDMOは、ウイルスベクターやmRNAベースの治療薬用の高密閉施設を含む、バイオ医薬品製造能力に多額の投資を行うようになっています。

もう一つの大きな動向は、IND CDMOサービスの世界化であり、各社は北米、欧州、アジア太平洋地域で事業を拡大しています。新興市場、特に中国とインドでは、コストメリット、熟練労働者の確保、医薬品のアウトソーシングを促進する政府の好意的な政策により、CDMOの能力が急速に伸びています。さらに、規制遵守と品質保証への注目の高まりは、CDMOが適正製造基準（GMP）ガイドラインを採用し、FDA、EMA、その他の世界の規制機関の要件を満たすために厳格な品質管理対策を実施することに影響を与えています。

さらに特筆すべき動向は、臨床開発スケジュールの早期化が重視されるようになっていることです。製薬業界が画期的な治療薬の迅速な承認を優先する中、CDMOは迅速なIND申請をサポートする能力を強化しています。これには、製剤化、分析試験、臨床試験供給管理を単一の契約下で行う統合的な医薬品開発ソリューションの提供が含まれ、タイムラインの短縮とプロジェクト効率の向上を実現しています。分散型臨床試験（DCT）の採用が増加していることも、CDMOが臨床サプライチェーンを遠隔地やハイブリッド試験モデルの需要に適合させることに影響を与えています。

IND CDMO市場の成長の原動力は？

治験薬CDMO市場の成長は、医薬品研究開発投資の増加、医薬品分子の複雑化、バイオ医薬品企業のアウトソーシングニーズの高まりなど、いくつかの要因によって牽引されています。特に、腫瘍学、神経学、希少疾患における新規治療薬のパイプラインが拡大していることが主要な促進要因となっています。多くの製薬企業が精密医療や標的治療に注力する中、CDMOは複雑な医薬品候補に合わせた専門的な製剤・分析サービスへの需要が高まっています。

市場成長を後押しするもう一つの重要な要因は、生物製剤や細胞・遺伝子治療の採用が増加していることです。先進的な治療法に対する需要の急増により、高密度の製造設備とウイルスベクター製造、mRNA技術、再生医療に関する専門知識を備えたCDMOに対するニーズが高まっています。さらに、希少疾病用医薬品の指定や、FDAのファスト・トラックやブレークスルー・セラピー指定などの迅速な規制経路の増加により、製薬会社は臨床開発や規制当局の承認プロセスを迅速化するため、機敏で能力の高いCDMOパートナーを求めるようになっています。

バーチャル・バイオテクノロジー・モデルへの戦略的シフトも、IND CDMOサービスへの需要を煽っています。中小規模のバイオテクノロジー企業の多くは、社内に製造および薬事規制の能力を持たないため、アウトソーシングは新薬候補の開発を進める上で不可欠な戦略となっています。さらに、早期臨床開発における厳格な規制要件により、製薬会社は規制コンサルティング、リスク軽減戦略、GMP準拠の製造を提供する経験豊富なCDMOとの提携を迫られています。最後に、治験薬を共同開発・製造するために大手製薬会社とCDMOが提携する傾向が強まっており、革新的な治療が高品質な基準を維持しながらより早く臨床試験に到達することを保証し、市場開拓をさらに促進しています。

セグメント

製品（低分子、高分子）、サービス（開発受託、製造受託）、エンドユーザー（製薬企業、バイオテクノロジー企業、その他）

調査対象企業の例

  • AGC Biologics
  • Aurigene Discovery
  • Bachem Holding AG
  • BioCina
  • Biocon
  • Cambrex Corporation
  • Catalent
  • Emergent BioSolutions
  • Fujifilm Diosynth
  • Hovione
  • Jubilant Pharmova
  • Laurus Labs
  • Lonza Group
  • Recipharm AB
  • Samsung Biologics
  • Siegfried Holding AG
  • Syngene International Ltd.
  • Thermo Fisher Scientific
  • WuXi AppTec
  • WuXi Biologics

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP31685

Global Investigational New Drug CDMO Market to Reach US$15.8 Billion by 2030

The global market for Investigational New Drug CDMO estimated at US$11.3 Billion in the year 2024, is expected to reach US$15.8 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Small Molecule, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$9.7 Billion by the end of the analysis period. Growth in the Large Molecule segment is estimated at 7.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 5.7% CAGR

The Investigational New Drug CDMO market in the U.S. is estimated at US$3.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 5.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.2% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Investigational New Drug CDMO Market - Key Trends & Growth Drivers Summarized

The Contract Development and Manufacturing Organization (CDMO) market for Investigational New Drugs (INDs) has become a critical component in the pharmaceutical and biotechnology industries. As pharmaceutical companies continue to focus on innovation while outsourcing drug development and manufacturing, CDMOs play a vital role in accelerating the path from preclinical research to clinical trials. IND CDMOs specialize in offering end-to-end solutions, including formulation development, clinical trial material manufacturing, regulatory support, and analytical services, enabling pharmaceutical firms to navigate the complex drug approval process efficiently. Given the increasing complexity of drug molecules, stringent regulatory requirements, and growing demand for specialized expertise, the role of CDMOs in the IND market is expanding rapidly, shaping the future of drug development worldwide.

How Are Technological Advancements Transforming IND CDMO Services?

The IND CDMO market is undergoing a significant transformation driven by technological innovations that enhance efficiency, compliance, and speed in drug development. One of the most important advancements is the integration of continuous manufacturing techniques, which streamline production processes, minimize waste, and improve product consistency. Unlike traditional batch manufacturing, continuous manufacturing allows for real-time quality monitoring, reducing the risk of variability and improving scalability for early-phase drug production.

Another breakthrough in the industry is the use of artificial intelligence (AI) and machine learning (ML) in drug formulation and process optimization. AI-driven predictive modeling helps CDMOs identify the most effective drug formulations, optimize stability conditions, and enhance process efficiencies. Additionally, automation and robotics in laboratory and manufacturing environments have improved precision in compound handling, minimizing human errors and ensuring reproducibility in IND production. The adoption of single-use bioprocessing technologies is another trend gaining momentum, particularly in biologics and cell and gene therapy manufacturing. These disposable systems reduce contamination risks, lower operational costs, and enhance flexibility, making them ideal for early-stage clinical production.

What Market Trends Are Reshaping the IND CDMO Landscape?

The IND CDMO market is witnessing several key trends that are reshaping its growth trajectory. One of the most prominent trends is the increasing demand for specialized CDMO services in biologics and advanced therapies. With the rapid expansion of monoclonal antibodies, cell and gene therapies, and RNA-based drugs, pharmaceutical companies are seeking CDMOs with expertise in handling complex biologic formulations, requiring specialized infrastructure and regulatory knowledge. This shift is prompting many CDMOs to invest heavily in biopharmaceutical production capabilities, including high-containment facilities for viral vector and mRNA-based therapeutics.

Another significant trend is the globalization of IND CDMO services, with companies expanding their operations across North America, Europe, and Asia-Pacific. Emerging markets, particularly in China and India, are witnessing rapid growth in CDMO capabilities due to cost advantages, skilled workforce availability, and favorable government policies promoting pharmaceutical outsourcing. Additionally, the rising focus on regulatory compliance and quality assurance is influencing CDMOs to adopt Good Manufacturing Practice (GMP) guidelines and implement stringent quality control measures to meet the requirements of the FDA, EMA, and other global regulatory agencies.

A further notable trend is the growing emphasis on accelerated clinical development timelines. With the pharmaceutical industry prioritizing fast-track approvals for breakthrough therapies, CDMOs are enhancing their capabilities to support expedited IND submissions. This includes offering integrated drug development solutions that combine formulation, analytical testing, and clinical trial supply management under a single contract, reducing timelines and improving project efficiency. The increasing adoption of decentralized clinical trials (DCTs) is also influencing CDMOs to adapt their clinical supply chains to meet the demands of remote and hybrid trial models.

What Is Driving the Growth of the IND CDMO Market?

The growth in the Investigational New Drug CDMO market is driven by several factors, including rising pharmaceutical R&D investments, increasing complexity of drug molecules, and the growing need for outsourcing among biopharmaceutical companies. A key driver is the expanding pipeline of novel therapeutics, particularly in oncology, neurology, and rare diseases. With many pharmaceutical firms focusing on precision medicine and targeted therapies, CDMOs are witnessing heightened demand for specialized formulation and analytical services tailored to complex drug candidates.

Another crucial factor propelling market growth is the rising adoption of biologics and cell and gene therapies. The surge in demand for advanced therapeutic modalities has created a need for CDMOs equipped with high-containment manufacturing facilities and expertise in viral vector production, mRNA technology, and regenerative medicine. Furthermore, the increase in orphan drug designations and expedited regulatory pathways, such as the FDA’s Fast Track and Breakthrough Therapy designations, are pushing pharmaceutical firms to seek agile and highly capable CDMO partners to speed up clinical development and regulatory approval processes.

The strategic shift toward virtual biotech models is also fueling demand for IND CDMO services. Many small and mid-sized biotech companies lack in-house manufacturing and regulatory capabilities, making outsourcing an essential strategy for advancing their drug candidates. Additionally, stringent regulatory requirements in early-phase clinical development are compelling pharmaceutical companies to collaborate with experienced CDMOs that offer regulatory consulting, risk mitigation strategies, and GMP-compliant production. Lastly, the growing trend of CDMO partnerships with big pharma to co-develop and manufacture investigational drugs is further driving market expansion, ensuring that innovative therapies reach clinical trials faster while maintaining high-quality standards.

SCOPE OF STUDY:

The report analyzes the Investigational New Drug CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Small Molecule, Large Molecule); Service (Contract Development, Contract Manufacturing); End-Use (Pharmaceutical Companies, Biotech Companies, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

  • AGC Biologics
  • Aurigene Discovery
  • Bachem Holding AG
  • BioCina
  • Biocon
  • Cambrex Corporation
  • Catalent
  • Emergent BioSolutions
  • Fujifilm Diosynth
  • Hovione
  • Jubilant Pharmova
  • Laurus Labs
  • Lonza Group
  • Recipharm AB
  • Samsung Biologics
  • Siegfried Holding AG
  • Syngene International Ltd.
  • Thermo Fisher Scientific
  • WuXi AppTec
  • WuXi Biologics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Investigational New Drug CDMO - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Outsourcing of Early-Stage Drug Development Strengthens Business Case for IND-Focused CDMOs
    • Surge in Biotech Startup Activity Expands Demand for IND-Enabling Chemistry and Regulatory Support
    • Increasing Complexity of Preclinical and CMC Requirements Spurs CDMO Specialization in IND Preparation
    • FDA Emphasis on Data Integrity and Filing Quality Creates Demand for End-to-End IND Submission Services
    • Acceleration of Rare Disease and Orphan Drug Pipelines Drives IND CDMO Engagements in Niche Therapies
    • Emergence of RNA, Cell, and Gene Therapies Expands Need for Specialized IND-Enabling Manufacturing Platforms
    • Pharma Cost Pressures Fuel Outsourcing of Preclinical Manufacturing and IND Strategy to CDMOs
    • Globalization of Drug Discovery Ecosystems Unlocks Opportunities for Multiregional IND Consulting Services
    • Integration of Regulatory Strategy With CMC Activities Improves IND Timelines and Filing Success
    • Growth in First-in-Human Trials Drives Demand for Small-Scale GMP Production and Stability Testing
    • Increasing Demand for IND Readiness Packages in Accelerated Approval Pathways Spurs Early CDMO Involvement
    • Venture-Backed Biopharma Projects Require Rapid IND Activation, Fueling Agile CDMO Partnerships
    • CDMO Investments in Integrated Bioanalytical Services Expand IND Value Proposition
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Investigational New Drug CDMO Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Investigational New Drug CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Small Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Small Molecule by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Large Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Large Molecule by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Contract Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Contract Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Pharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Investigational New Drug CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 18: USA Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 19: USA 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030
  • CANADA
    • TABLE 24: Canada Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Canada 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030
  • JAPAN
    • Investigational New Drug CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 30: Japan Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Japan 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Japan 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030
  • CHINA
    • Investigational New Drug CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 36: China Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: China 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
    • TABLE 40: China Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: China 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030
  • EUROPE
    • Investigational New Drug CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 42: Europe Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 43: Europe 6-Year Perspective for Investigational New Drug CDMO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030
  • FRANCE
    • Investigational New Drug CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
    • TABLE 52: France Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: France 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
    • TABLE 54: France Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: France 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030
  • GERMANY
    • Investigational New Drug CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
    • TABLE 58: Germany Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Germany 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Germany 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
    • TABLE 64: Italy Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Italy 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030
  • UNITED KINGDOM
    • Investigational New Drug CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
    • TABLE 70: UK Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: UK 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
    • TABLE 72: UK Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Rest of Europe 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
    • TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Rest of Europe 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Investigational New Drug CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Asia-Pacific 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
    • TABLE 82: Asia-Pacific Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Asia-Pacific 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 86: Rest of World Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Product - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of World 6-Year Perspective for Investigational New Drug CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2025 & 2030
    • TABLE 88: Rest of World Recent Past, Current & Future Analysis for Investigational New Drug CDMO by Service - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of World 6-Year Perspective for Investigational New Drug CDMO by Service - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2025 & 2030
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Investigational New Drug CDMO by End-Use - Pharmaceutical Companies, Biotech Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of World 6-Year Perspective for Investigational New Drug CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biotech Companies and Others for the Years 2025 & 2030

IV. COMPETITION